How Can Medtechs Prepare for the FDA’s Shift Left Strategy on Cybersecurity?
This article originally appeared in MedCity News on May 10, 2023.
The recent FDA guidance on security marks good and bad news for the industry. In short, the FDA can now refuse submissions from medical device manufacturers if they can’t demonstrate that they have comprehensive cybersecurity processes and detailed information on the composition of their software in place. This is good news for the public and healthcare industry in general.
While the FDA has published a number of plans to address medical device problems post-market, its plans and processes for addressing cybersecurity issues have been woefully inadequate. Regulators have become increasingly concerned about the potential for medical devices to become a vector for spreading malware attacks across hospital networks, resulting in untold patient harm and billions of dollars globally.
Erez is passionate about improving patient care and health outcomes with software solutions. Over the last decade, Erez worked in industries including computational mathematics, biotech, and energy, helping build monitoring systems for pharmaceutical equipment and AI for medication management. Before Ketryx, Erez worked with Amgen, the world’s largest biotechnology company, as the head of AI/ML for their medical device division and with Wolfram Research, the builders of Mathematica and Wolfram|Alpha. Erez holds a Master of Science in Electrical Engineering and Computer Science and a Master of Business Administration from the Massachusetts Institute of Technology.
